Panning for Prostate Gold: Urine Based Markers for Prostate Cancer

Journal of Urology

Volumn 181, Issue 1, 2009, Pages 9-10

  Konety, Badrinath R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; GLUTATHIONE TRANSFERASE P1; GLYCEROPHOSPHOINOSITOL INOSITOLPHOSPHODIESTERASE; PROSTATE SPECIFIC ANTIGEN; RNA; TUMOR MARKER;

CANCER RISK; CANCER SCREENING; EDITORIAL; HUMAN; NEEDLE BIOPSY; PRIORITY JOURNAL; PROSTATE CANCER;

ANNEXIN A3; BIOLOGICAL MARKERS; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 57149107117     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2008.10.079     Document Type: Editorial

References (6)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71
2. Bartsch G., Horninger W., Klocker H., Pelzer A., Bektic J., Oberaigner W., et al. Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. BJU Int 101 (2008) 809
3. de Vries S.H., Postma R., Raaijmakers R., Roemeling S., Otto S., de Koning H.J., et al. Overall and disease-specific survival of patients with screen-detected prostate cancer in the European Randomized Study of Screening for Prostate Cancer, Section Rotterdam. Eur Urol 51 (2007) 366
4. Stamey T.A., Caldwell M., McNeal J.E., Nolley R., Hemenez M., and Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?. J Urol 172 (2004) 1297
5. Thompson I.M., Pauler D.K., Goodman P.J., Tangen C.M., Lucia M.S., Parnes H.L., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 350 (2004) 2239
6. Downes M.R., Byrne J.C., Pennington S.R., Dunn M.J., Fitzpatrick J.M., and Watson R.W. Urinary markers for prostate cancer. BJU Int 99 (2007) 263